348 results on '"Baoan Chen"'
Search Results
2. Targeting BET proteins inhibited the growth of non‐small cell lung carcinoma through downregulation of Met expression
- Author
-
Ting Yuan, Ping Ni, Zuhao Zhang, Dandan Wu, Geng Sun, Haijun Zhang, Baoan Chen, Xuerong Wang, and Zhixiang Cheng
- Subjects
Cell Biology ,General Medicine - Abstract
Hepatocyte growth factor receptor (HGFR or Met) upregulation has been proven to play important roles in non-small cell lung carcinoma (NSCLC). Interestingly, chemoresistance against epidermal growth factor receptor (EGFR) inhibitors including erlotinib and gefitinib was also related to Met. Targeting bromodomain and extra terminal domain (BET) proteins, especially BRD4, has shown inhibitory effects on lung cancer, but the mechanism is unclear. Herein, we found that JQ1 (BET inhibitor) suppressed NSCLC cell growth, reduced the Met expression, and contributed to inactivation of PI3K/Akt and MAPK/ERK pathways. Moreover, another BET protein inhibitor I-BET151, or BRD4 depletion, also inhibited NSCLC cell growth and downregulated Met. JQ1 inhibited HGF-induced cell growth and Met/PI3K/Akt activation, also inhibited A549 tumor growth in xenograft mouse models, in parallel with Met downregulation. Moreover, JQ1 inhibited the growth of paired erlotinib-sensitive and resistant HCC827 cells in parallel with Met downregulation and PI3K/Akt signaling inactivation. JQ1 also exerted inhibitory influences on the growth of erlotinib-sensitive and resistant HCC827 tumors in xenograft mouse models. These results suggested that targeting BET proteins inhibited NSCLC via downregulating Met and inactivating PI3K/AKT pathway. Our findings reveal a novel mechanism of BET proteins implicated in NSCLC progression with Met taken into consideration.
- Published
- 2022
3. Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma
- Author
-
Peng Yuan, Jinhua Song, Fei Wang, Guangyu Zhu, and Baoan Chen
- Subjects
Pharmacology ,Carcinoma, Hepatocellular ,Phenylurea Compounds ,Liver Neoplasms ,Cholangiocarcinoma ,Bile Ducts, Intrahepatic ,Treatment Outcome ,Bile Duct Neoplasms ,Oncology ,Quinolines ,Humans ,Pharmacology (medical) ,Chemoembolization, Therapeutic ,Retrospective Studies - Abstract
Conversion therapy has been widely applied in various cancer types including intrahepatic cholangiocarcinoma (ICC). The aim of this retrospective study was to evaluate the efficacy and safety of transarterial chemoembolization combined with lenvatinib (TACE-L) as a novel conversion therapy in patients with initially unresectable ICC.Enrolled in this retrospective study were patients with unresectable ICC who received TACE-L between January 2015 and May 2018. The patients were evaluated every 2 months for possible secondary resection.Of the 44 eligible patients, 28 (63.6%) were successfully downstaged to receive surgical resection and the other 16 patients were included into the unsuccessfully downstaged group. The overall adverse events during TACE-L were moderate, including 12 patients (27.3%) with Grade 3 or 4 toxicities. Of the 28 downregulated patients, 23 (82.1%) achieved an R0 resection, and 6 (21.4%) had Clavien-Dindo grade ≥ 3 complications, including one postoperative death. Kaplan-Meier curves showed that the successfully downstaged patients had better overall survival (OS) than the unsuccessfully downstaged patients (P = 0.006). Multivariable analysis identified successful TACE-L conversion therapy as a significantly favorable prognostic factor for OS.TACE-L proves to be a safe and efficacious conversion therapy modality that allows for secondary resectability in patients with initially unresectable ICC.
- Published
- 2022
4. GOx-Functionalized Platelet Membranes-Camouflaging Nanoreactors for Enhanced Multimodal Tumor Treatment
- Author
-
Ying Du, Shujun Wang, Jianfeng Luan, Meilin Zhang, Baoan Chen, and Yanfei Shen
- Subjects
Organic Chemistry ,Biophysics ,Pharmaceutical Science ,Oxides ,Bioengineering ,Hydrogen Peroxide ,General Medicine ,Sulfides ,Biomaterials ,Glucose Oxidase ,Manganese Compounds ,International Journal of Nanomedicine ,Doxorubicin ,Cell Line, Tumor ,Neoplasms ,Drug Discovery ,Tumor Microenvironment ,Humans ,Nanoparticles ,Nanotechnology - Abstract
Ying Du,1,2 Shujun Wang,3 Jianfeng Luan,3 Meilin Zhang,1,2 Baoan Chen,1,2,* Yanfei Shen2,* 1Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, Peopleâs Republic of China; 2School of Medicine, Southeast University, Nanjing, Jiangsu, Peopleâs Republic of China; 3Department of Blood Transfusion, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, Peopleâs Republic of China*These authors contributed equally to this workCorrespondence: Baoan Chen, Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, 210009, Peopleâs Republic of China, Email cba8888@hotmail.com Yanfei Shen, School of Medicine, Southeast University, Nanjing, Jiangsu, 210009, Peopleâs Republic of China, Email Yanfei.Shen@seu.edu.cnBackground: Glucose oxidase (GOx)-based starvation therapy is a new cancer treatment strategy. However, the characteristics such as limited curative effect and hypoxic tumor environment hinder its further application seriously.Methods: Herein, doxorubicin (DOX) loaded in hollow mesoporous copper sulfide (HMCuS) nanoparticles assembled with manganese dioxide (HMMD) as nanoshell was prepared. We developed a targeted enhanced cancer treatment method to camouflage HMMD by GOx-functionalized platelet (PLT) membranes (HMMD@PG).Results: GOx can be specially transported to the tumor site with PLT membrane for effective starvation treatment. Glucose and oxygen (O2) in the tumor were converted to H2O2 under the catalysis of GOx. HMMD can catalyze H2O2 to produce O2 and consume glutathione (GSH) in time, which regulates the tumor microenvironment (TME) and improves the adverse conditions of anti-tumor. In addition, DOX encapsulated in HMCuS-MnO2 release was accelerated from the nanoparticles after the âgatekeeperâ MnO2 is consumed. The study of anti-tumor mechanism shows that the remarkable tumor suppressive ability of HMMD@PG comes from the three peaks synergy of starvation treatment, photothermal treatment (PTT), and chemotherapy. This nanoplatform disguised by PLT membrane has significant tumor inhibition ability, good biocompatibility and almost has no side effects in main organs.Conclusion: This work broadens the application mode of GOx and shows the new development of a multi-mode collaborative processing system of nanoplatforms based on cell membrane camouflage.Keywords: glucose oxidase, PLT membrane, nanoparticles, tumor microenvironment, tumor treatment
- Published
- 2022
5. Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia
- Author
-
Zheng, Shi, Yiqian, Zhu, Jing, Zhang, and Baoan, Chen
- Subjects
Antineoplastic Agents, Immunological ,Neoplasm, Residual ,Antibodies, Monoclonal ,Humans ,Antineoplastic Agents ,Inotuzumab Ozogamicin ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Burkitt Lymphoma - Abstract
This review aims to see the progress of several clinically-used monoclonal antibodies in treating ALL patients and how they improved patients' outcomes.We searched Web of Science, Elsevier and PubMed for relevant published studies, and summarized eligible evidence on the management of newly-diagnosed and relapsed or refractory ALL with monoclonal antibodies. Ongoing trials were identified from ClinicalTrials.gov.Rituximab, an anti-CD20 monoclonal antibody, prolonged patients' complete remission duration and overall survival when combined with hyper-CVAD regimen. Another anti-CD20 monoclonal antibody, Ofatumumab, was reported to have similar benefits. Blinatumomab allows endogenous CD3-positive cytotoxic T cells to target and eliminate CD19-positive blasts. FDA has approved its efficacy in patients with R/R B-ALL and eliminating minimal residual disease (MRD). It serves as a bridge to eradicate MRD before transplantation, and may also be a new choice for patients unable to undergo transplantation. An anti-CD22 monoclonal antibody named Inotuzumab Ozogamicin showed great improvement in patients' outcome, but its toxicity to liver is also worthy of our attention.Monoclonal antibodies are proven to be a promising immunotherapeutic strategy to improve ALL patients' outcome in the long term. There's still a need for individualized treatment with effective and well-tolerated medicines.
- Published
- 2022
6. Allogeneic platelet gel therapy for refractory abdominal wound healing: A preliminary study
- Author
-
shujun wang, Weiwei Ding, Ying Du, Qing Qi, Kaiyun Luo, Jianfeng Luan, Yanfei Shen, and Baoan Chen
- Subjects
Reviews and References (medical) ,Internal Medicine ,Medicine (miscellaneous) ,Pharmacology (medical) ,General Biochemistry, Genetics and Molecular Biology ,Genetics (clinical) - Published
- 2023
7. New insights into genetic characteristics between multiple myeloma and COVID‐19: An integrative bioinformatics analysis of gene expression omnibus microarray and the cancer genome atlas data
- Author
-
Ran Liu, Jie Yang, Baoan Chen, and Fei Wang
- Subjects
Gene Expression Regulation, Viral ,Oncology ,bioinformatics analysis ,medicine.medical_specialty ,Microarray ,Coronavirus disease 2019 (COVID-19) ,overall survival ,Clinical Biochemistry ,Nod2 Signaling Adaptor Protein ,Datasets as Topic ,Kaplan-Meier Estimate ,Biology ,Electron Transport Complex IV ,coronavirus disease 2019 ,NOD2 ,Internal medicine ,medicine ,Humans ,Protein Interaction Maps ,Gene ,Multiple myeloma ,Proportional Hazards Models ,Covid‐19 ,Integrative bioinformatics ,SARS-CoV-2 ,Proportional hazards model ,Gene Expression Profiling ,Biochemistry (medical) ,COVID-19 ,Computational Biology ,Original Articles ,Hematology ,General Medicine ,Microarray Analysis ,Prognosis ,medicine.disease ,Neoplasm Proteins ,Gene Expression Regulation, Neoplastic ,multiple myeloma ,Gene Ontology ,Cohort ,Original Article - Abstract
Background Multiple myeloma (MM) is a hematological malignancy. Coronavirus disease 2019 (COVID‐19) infection correlates with MM features. This study aimed to identify MM prognostic biomarkers with potential association with COVID‐19. Methods Differentially expressed genes (DEGs) in five MM data sets (GSE47552, GSE16558, GSE13591, GSE6477, and GSE39754) with the same expression trends were screened out. Functional enrichment analysis and the protein‐protein interaction network were performed for all DEGs. Prognosis‐associated DEGs were screened using the stepwise Cox regression analysis in the cancer genome atlas (TCGA) MMRF‐CoMMpass cohort and the GSE24080 data set. Prognosis‐associated DEGs associated with COVID‐19 infection in the GSE164805 data set were also identified. Results A total of 98 DEGs with the same expression trends in five data sets were identified, and 83 DEGs were included in the protein‐protein interaction network. Cox regression analysis identified 16 DEGs were associated with MM prognosis in the TCGA cohort, and only the cytochrome c oxidase subunit 6C (COX6C) gene (HR = 1.717, 95% CI 1.231–2.428, p = .002) and the nucleotide‐binding oligomerization domain containing 2 (NOD2) gene (HR = 0.882, 95% CI 0.798–0.975, p = .014) were independent factors related to MM prognosis in the GSE24080 data set. Both of them were downregulated in patients with mild COVID‐19 infection compared with controls but were upregulated in patients with severe COVID‐19 compared with patients with mild illness. Conclusions The NOD2 and COX6C genes might be used as prognostic biomarkers in MM. The two genes might be associated with the development of COVID‐19 infection.
- Published
- 2021
8. Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating non-Hodgkin lymphoma: A systematic review and meta-analysis of clinical trials
- Author
-
Jiaheng Guan, Jing Zhang, Xiaoping Zhang, Zhongshu Yuan, Jian Cheng, and Baoan Chen
- Subjects
Lung Neoplasms ,Lymphoma, Non-Hodgkin ,Programmed Cell Death 1 Receptor ,Humans ,Apoptosis ,General Medicine ,Immune Checkpoint Inhibitors ,Hodgkin Disease ,B7-H1 Antigen - Abstract
Immunotherapy with programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors has been widely used in the treatment of solid tumors and Hodgkin lymphoma, demonstrating powerful efficacy and good safety. However, there is no systematic review and meta-analysis to fully investigate the efficacy and safety of PD-1/PD-L1 inhibitors in treating non-Hodgkin lymphoma (NHL).We searched PubMed, EMBASE, The Cochrane Library, China National Knowledge Infrastructure, Wanfang database, and abstracts of conference proceedings of annual meetings up to January 23, 2022, to identify eligible clinical trials. To evaluate the efficacy of PD-1/PD-L1 inhibitors, objective response rate (ORR), complete response rate (CRR), 1-year overall survival rate, and 1-year progression-free survival rate were analyzed. For safety analysis, we calculated rates of any grade and grade ≥3 treatment-related adverse events.Overall 22 studies and 1150 participants were enrolled in this meta-analysis. The pooled ORR, CRR, 1-year overall survival, and 1-year progression-free survival rates were 0.43 (95% confidence interval [CI], 0.33-0.54), 0.21 (95% CI, 0.13-0.31), 0.72 (95% CI, 0.58-0.89), and 0.42 (95% CI, 0.29-0.62), respectively. The ORR and CRR in the combination immunochemotherapy subgroup (0.65 and 0.41) were higher than those in the monotherapy (0.27 and 0.09) and combination chemotherapy (0.39 and 0.19) subgroups. This study was registered with PROSPERO (#CRD 42022316805).Given that there were limited clinical trials and relatively few relevant studies, we conducted this meta-analysis to fully elucidate the efficacy and safety of PD-1/PD-L1 inhibitors in NHL. Our results suggested that PD-1/PD-L1 inhibitors improved outcomes of responses as well as survival rates in NHL patients with tolerable adverse events. More well-designed randomized clinical trials are still needed to further confirm our findings.
- Published
- 2022
9. CCAT1/FABP5 promotes tumour progression through mediating fatty acid metabolism and stabilizing PI3K/AKT/mTOR signalling in lung adenocarcinoma
- Author
-
Jing Chen, Xiaoli Zhu, Baoan Chen, Kai Zhang, and Yaser Alduais
- Subjects
Angiogenesis ,Adenocarcinoma of Lung ,ubiquitination ,Fatty Acid-Binding Proteins ,Models, Biological ,angiogenesis ,Mice ,Phosphatidylinositol 3-Kinases ,Downregulation and upregulation ,Transcription (biology) ,Cell Line, Tumor ,Animals ,Humans ,Protein kinase B ,PI3K/AKT/mTOR pathway ,Neovascularization, Pathologic ,Oncogene ,Chemistry ,Cell growth ,TOR Serine-Threonine Kinases ,Fatty Acids ,CCAT1 ,RNA-Binding Proteins ,Original Articles ,Cell Biology ,lung adenocarcinoma ,Lipid Metabolism ,Disease Models, Animal ,Protein Transport ,fatty acid metabolism ,Disease Progression ,Cancer research ,Heterografts ,Molecular Medicine ,Original Article ,RNA, Long Noncoding ,Signal transduction ,Proto-Oncogene Proteins c-akt ,Protein Binding ,Signal Transduction - Abstract
Long non‐coding RNA (lncRNA) colon cancer associated transcript 1 (CCAT1) has been identified as an oncogene in many cancers, but its role in lung adenocarcinoma (LUAD) remains to be further investigated. We identified the upregulation of CCAT1 in LUAD tissues and LUAD cells. Through RNA pull‐down and mass spectrometry analysis, we obtained the interacting proteins with CCAT1 and discovered their functional relation with ‘signal transduction’, ‘energy pathways’ and ‘metabolism’ and revealed the potential of CCAT1 on fatty acid (FA) metabolism. For mechanism exploration, we uncovered the mediation of CCAT1 on the translocation of fatty acid binding protein 5 (FABP5) into nucleus by confirming their interaction and localization. Also, CCAT1 was discovered to promote the formation of the transcription complex by RXR and PPARγ so as to activate the transcription of CD36, PDK1 and VEGFA. Moreover, we found that CCAT1 regulated the activity of AKT by promoting the ubiquitination of FKBP51 through binding with USP49. Subsequently, cell function assays revealed the enhancement of CCAT1 on LUAD cell proliferation and angiogenesis in vitro and in vivo. Collectively, CCAT1 regulated cell proliferation and angiogenesis through regulating FA metabolism in LUAD, providing a novel target for LUAD treatment.
- Published
- 2021
10. Correlation between lymphoma and second primary malignant tumor
- Author
-
Lingjuan Liu, Qun Zhang, and Baoan Chen
- Subjects
General Medicine - Published
- 2023
11. Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group
- Author
-
Huisheng Ai, Nelson J. Chao, David A. Rizzieri, Xiaojun Huang, Thomas R. Spitzer, Jianxiang Wang, Mei Guo, Armand Keating, Elizabeth F. Krakow, Didier Blaise, Jun Ma, Depei Wu, John Reagan, Usama Gergis, Rafael F. Duarte, Preet M. Chaudhary, Kaixun Hu, Changlin Yu, Qiyun Sun, Ephraim Fuchs, Bo Cai, Yajing Huang, Jianhui Qiao, David Gottlieb, Kirk R. Schultz, Mingyao Liu, Xiequn Chen, Wenming Chen, Jianmin Wang, Xiaohui Zhang, Jianyong Li, He Huang, Zimin Sun, Fei Li, Linhua Yang, Liansheng Zhang, Lijuan Li, Kaiyan Liu, Jie Jin, Qifa Liu, Daihong Liu, Chunji Gao, Chuanbo Fan, Li Wei, Xi Zhang, Liangding Hu, Weijing Zhang, Yuyang Tian, Weidong Han, Jun Zhu, Zhijian Xiao, Daobin Zhou, Bolong Zhang, Yongqian Jia, Yongqing Zhang, Xiaoxiong Wu, Xuliang Shen, Xuzhang Lu, Xinrong Zhan, Xiuli Sun, Yi Xiao, Jingbo Wang, Xiaodong Shi, Bo Zheng, Jieping Chen, Banghe Ding, Zhao Wang, Fan Zhou, Mei Zhang, Yizhuo Zhang, Jie Sun, Bing Xia, Baoan Chen, and Liangming Ma
- Subjects
Multidisciplinary ,Review Article - Abstract
Recent studies have shown that microtransplant (MST) could improve outcome of patients with elderly acute myeloid leukemia (EAML). To further standardize the MST therapy and improve outcomes in EAML patients, based on analysis of the literature on MST, especially MST with EAML from January 1st, 2011 to November 30th, 2022, the International Microtransplant Interest Group provides recommendations and considerations for MST in the treatment of EAML. Four major issues related to MST for treating EAML were addressed: therapeutic principle of MST (1), candidates for MST (2), induction chemotherapy regimens (3), and post-remission therapy based on MST (4). Others included donor screening, infusion of donor cells, laboratory examinations, and complications of treatment.
- Published
- 2023
12. Exosome-transmitted circ_002136 promotes hepatocellular carcinoma progression by miR-19a-3p/RAB1A pathway
- Author
-
Peng Yuan, Jinhua Song, Fei Wang, and Baoan Chen
- Subjects
Cancer Research ,MicroRNAs ,Carcinoma, Hepatocellular ,Oncology ,Liver Neoplasms ,Genetics ,Tumor Microenvironment ,Humans ,RNA, Circular ,Exosomes - Abstract
Background Circular RNAs (circRNAs) are enriched in exosomes and are extremely stable. Exosome-mediated intercellular transfer of specific biologically active circRNA molecules can drive the transformation of the tumor microenvironment and accelerate or inhibit the local spread and multifocal growth of hepatocellular carcinoma (HCC). In this study, we explored in depth about the biological roles of HCC cell-derived exosomes and exosome-transported circRNAs on HCC in vivo and in vitro. Methods Exosomes extracted from HCC cells (Huh7 and HA22T) were characterized using transmission electron microscopy, nanoparticle size tracer analysis, and western blotting. Exosomes were observed for endocytosis using fluorescent labeling. The effects of HCC cell-derived exosomes and the circ_002136 they carried on cell growth, metastasis and apoptosis were determined by CCK-8 assay, transwell assay, flow cytometry analysis and TUNEL staining, respectively. The expressions of circ_002136, miR-19a-3p and RAB1A were detected by quantitative RT-PCR (qRT-PCR). Targeted binding between miR-19a-3p and circ_002136 or RAB1A was predicted and verified by bioinformatics analysis, dual-luciferase reporter and RNA pull-down experiments. The in vivo effect of circ_002136 was determined by constructing a xenograft tumor model. Results The findings revealed that Huh7 and HA22T exosomes conferred enhanced viability as well as invasive ability to recipient HCC cells. Circ_002136 was shown for the first time to be differentially upregulated in HCC tissues and cells and transferred by HCC cell-derived exosomes. More importantly, selective silencing of circ_002136 depleted the malignant biological behaviors of HCC exosome-activated Huh7 and HA22T cells. Depletion of circ_002136 in vivo effectively retarded the growth of HCC xenograft tumors. Furthermore, a well-established circ_002136 ceRNA regulatory network was constructed, namely circ_002136 blocked miR-19a-3p expression, elevated RAB1A expression activity and stimulated HCC development. Finally, high levels of circ_002136 or RAB1A, as well as low levels of miR-19a-3p, negatively affected HCC patient survival. Conclusion The study on circ_002136 provides good data to support our insight into the mechanism of to-be-silenced circRNA as a therapeutic agent in the progression of HCC.
- Published
- 2022
13. Therapy‑related acute myeloid leukemia: A case series
- Author
-
Jie, Yang and Baoan, Chen
- Subjects
Cancer Research ,Oncology - Abstract
Patients with primary cancer receiving chemotherapy and/or radiotherapy may develop therapy-related acute leukemia (t-AL). Therapy-related acute myeloid leukemia (t-AML) accounts for the majority of these cases and is frequently associated with a variety of cytogenetic and molecular abnormalities. The aim of the present study was to explore the clinical characteristics, treatments and prognosis of patients with t-AML. A total of 272 cases of AML treated at our institution between 2016 and 2020 were reviewed, among which nine cases of t-AML were identified for analysis. All patients had received alkylating or topoisomerase II inhibitor chemotherapy drugs for primary cancer treatment and three patients had received radiotherapy. A total of nine patients had been administered recombinant human granulocyte colony-stimulating factor (G-CSF). The median latency period for the nine patients with t-AML was 25 months (range, 10-240 months). The molecular cytogenetic abnormalities included t(15:17)(q22:q21), inv(16)(p13q22), del(5)(q22), CBFB/MYH11(+), FLT3(+), NARS(+), IDH(+), TET2(+), and TP53(+). Out of nine patients with t-AML, eight received chemotherapy, two of whom underwent HSCT. The median survival time of the nine patients with t-AML was 10 months and the 2-year-survival rate was 44.4%. Greater clarity around the diagnosis and treatment is required to improve the outcomes of patients with t-AML.
- Published
- 2022
14. Current applications of platelet gels in wound healing—A review
- Author
-
Luan Jianfeng, Shen Yanfei, Baoan Chen, Wang Shujun, Jie Yang, Guangchao Zhao, Ying Du, Zhimei Cai, and Ran Liu
- Subjects
Blood Platelets ,Dermatology ,Disease ,Pharmacology ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Thrombin ,Animals ,Humans ,Medicine ,Platelet ,Wound Healing ,Platelet-Rich Plasma ,business.industry ,medicine.disease ,Thrombosis ,Platelet-rich plasma ,Intercellular Signaling Peptides and Proteins ,Surgery ,Epidermolysis bullosa ,Wound healing ,business ,Gels ,medicine.drug - Abstract
Human platelets play important roles in several physiologic and pathologic processes. Platelet concentrates are activated with thrombin or calcium, resulting in a viscous coagulum (platelet gel [PG]), composed of 95% platelets at least. PG is increasingly used for the treatment of a variety of soft and hard tissue defects, most notably in the management of chronic non-healing wounds. During wound healing, platelets not only play a critical role in primary hemostasis and thrombosis, but also release growth factors and cytokines to promote tissue regeneration, enhance collagen synthesis, and trigger an immune response. This review addresses a variety of aspects relevant to the functions of well-known platelet growth factors, animal and clinical studies of PG in the last decade, and different sources of platelets for PG. PG is used for non-healing chronic wounds, such as oral ulcerations related to epidermolysis bullosa and chronic graft-versus-host disease, for those, the traditional treatment effect is poor. PG maybe provide a new therapeutic direction for these diseases. Nevertheless, some uncertainty is present, the number of clinical studies is not enough. Hence, randomized controlled trials are still required to study the potential of the use of PG in the near future.
- Published
- 2021
15. Identification of hub genes with prognostic values in multiple myeloma by bioinformatics analysis
- Author
-
Jie Yang, Baoan Chen, Shanliang Zhong, and Fei Wang
- Subjects
Hub genes ,Bioinformatics analysis ,Biology ,Malignant disease ,Pathogenesis ,03 medical and health sciences ,0302 clinical medicine ,Databases, Genetic ,medicine ,Humans ,Gene Regulatory Networks ,Target therapy ,Multiple myeloma ,Gene Expression Profiling ,RNA Polymerase III ,Ketone Oxidoreductases ,Genomics ,Hematology ,Hypoxia (medical) ,Prognosis ,medicine.disease ,Gene Expression Regulation, Neoplastic ,Gene Ontology ,030220 oncology & carcinogenesis ,Cancer research ,medicine.symptom ,Carbohydrate Epimerases ,Multiple Myeloma ,Transcriptome ,030215 immunology - Abstract
Multiple myeloma (MM) is a malignant disease with abnormal proliferation of clonal plasma cells. Hypoxia is an important factor in the pathogenesis and development of MM. However, the underlying mechanisms are not fully understood.To determine hub genes related to hypoxia in MM, this study took integrated bioinformatics analysis with two expression datasets (GSE80140 and GSE80545) downloaded from Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were filtrated under the condition of bothIn total, three hub genes, including FH, TSTA3, and POLR3G, were screened out to be related to hypoxia in MM. Patients with the lower expression level of FH, TSTA3, and POLR3G have statistically significantly longer disease- specific survival (CoxWe identified FH, TSTA3, and POLR3G as hub genes which can affect MM patients'outcome and new biomarkers for diagnosis and prognosis of MM. Further functional and mechanistic studies are need to develop in order to make them as potential target for clinical treatment.
- Published
- 2021
16. Prognostic significance of ferroptosis-related genes and their methylation in AML
- Author
-
Fang Zhou and Baoan Chen
- Subjects
Oncology ,medicine.medical_specialty ,Suppressor of Cytokine Signaling 1 Protein ,Internal medicine ,Databases, Genetic ,Cox proportional hazards regression ,Biomarkers, Tumor ,medicine ,Ferroptosis ,Humans ,Gene Regulatory Networks ,Genetic Predisposition to Disease ,In patient ,Gene ,Chromosome Aberrations ,Suppressor of cytokine signaling 1 ,business.industry ,Gene Expression Profiling ,Hydroxysteroid Dehydrogenases ,Computational Biology ,Reproducibility of Results ,Hematology ,Methylation ,DNA Methylation ,Prognosis ,Gene Expression Regulation, Neoplastic ,Leukemia, Myeloid, Acute ,Gene Ontology ,ROC Curve ,Ppi network ,DNA methylation ,Transcriptome ,business - Abstract
BACKGROUND Ferroptosis involves in the development and therapeutic response of various types of tumors. This study aims to explore ferroptosis-related prognostic genes that could further accurately stratify AML patients. METHODS We investigated the prognosis significance of ferroptosis-related genes in AML by Univariate and multivariate Cox proportional hazards regression analyses. With the methylation data of TCGA samples, we looked for methylation sites associated with prognostic genes and compared the correlation between methylation and mRNA expression. R software and 'edgeR' packages were used to identify the DEGs between the high-and-low-risk groups divided by the FRPGs prognosis model and then run GO enrichment, KEGG pathway, and PPI network. RESULTS We found a prognostic risk model that included AKR1C2 and SOCS1 predicted outcomes in AML patients. Methylation analysis showed that AKR1C2 and SOCS1 are negatively regulated by their methylation, leading to their low expression in AML patients. Besides, both decreased SOCS1 expression and hypermethylation predicted favorable OS and PFS in AML patients. Finally, this prognostic risk model exhibited a close correlation with several clinical features, especially with age (P=0.005), cytogenetic type (P=0.031), risk_cytogenetic (P=0.001), and risk_molecular (P
- Published
- 2021
17. Progress of Breast Cancer basic research in China
- Author
-
Baoan Chen, Jiaheng Guan, Ceshi Chen, Chao Wang, Xuerong Wang, and Lin Xu
- Subjects
cancer stem cells ,Oncology ,China ,medicine.medical_specialty ,Biomedical Research ,medicine.medical_treatment ,Breast Neoplasms ,Review ,Medical Oncology ,Applied Microbiology and Biotechnology ,Targeted therapy ,Metastasis ,03 medical and health sciences ,breast cancer ,Breast cancer ,Cancer stem cell ,Internal medicine ,medicine ,tumor microenvironment ,metastasis ,Humans ,Translational Science, Biomedical ,Molecular Biology ,Ecology, Evolution, Behavior and Systematics ,030304 developmental biology ,0303 health sciences ,Tumor microenvironment ,drug resistance ,Mechanism (biology) ,business.industry ,Cancer ,Cell Biology ,medicine.disease ,Cancer cell ,Female ,business ,Developmental Biology - Abstract
Breast cancer is the most commonly diagnosed and the most lethal cancer in females both in China and worldwide. Currently, the origin of cancer stem cells, the heterogeneity of cancer cells, the mechanism of cancer metastasis and drug resistance are the most important issues that need to be addressed. Chinese investigators have recently made new discoveries in basic breast cancer researches, especially regarding cancer stem cells, cancer metabolism, and microenvironments. These efforts have led to a deeper understanding of drug resistance and metastasis and have also indicated new biomarkers and therapeutic targets. These findings emphasized the importance of the cancer stem cells for targeted therapy. In this review, we summarized the latest important findings in this field in China.
- Published
- 2021
18. Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment
- Author
-
Yaser Alduais, Haijun Zhang, Fan Fan, Jing Chen, and Baoan Chen
- Subjects
General Medicine - Published
- 2023
19. Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review
- Author
-
Yi Zhang, Fang Zhou, Jiaheng Guan, Lukun Zhou, and Baoan Chen
- Subjects
Molecular Biology ,Biochemistry - Abstract
Hematologic malignancies (HMs) mainly include acute and chronic leukemia, lymphoma, myeloma and other heterogeneous tumors that seriously threaten human life and health. The common effective treatments are radiotherapy, chemotherapy and hematopoietic stem cell transplantation (HSCT), which have limited options and are prone to tumor recurrence and (or) drug resistance. Metformin is the first-line drug for the treatment of type 2 diabetes (T2DM). Recently, studies identified the potential anti-cancer ability of metformin in both T2DM patients and patients that are non-diabetic. The latest epidemiological and preclinical studies suggested a potential benefit of metformin in the prevention and treatment of patients with HM. The mechanism may involve the activation of the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway by metformin as well as other AMPK-independent pathways to exert anti-cancer properties. In addition, combining current conventional anti-cancer drugs with metformin may improve the efficacy and reduce adverse drug reactions. Therefore, metformin can also be used as an adjuvant therapeutic agent for HM. This paper highlights the anti-hyperglycemic effects and potential anti-cancer effects of metformin, and also compiles the in vitro and clinical trials of metformin as an anti-cancer and chemosensitizing agent for the treatment of HM. The need for future research on the use of metformin in the treatment of HM is indicated.
- Published
- 2023
20. Tetrandrine overcomes drug resistance mediated by bone marrow microenvironment by regulating the expression of P-glycoprotein in acute leukemia
- Author
-
Xinyi Zhou, Nan Jin, and Baoan Chen
- Subjects
Leukemia, Myeloid, Acute ,Bone Marrow ,Tumor Microenvironment ,Humans ,Hematology ,ATP Binding Cassette Transporter, Subfamily B, Member 1 ,Antineoplastic Agents, Phytogenic ,Benzylisoquinolines ,Drug Resistance, Multiple - Published
- 2022
21. The Significance of Inflammatory Markers in the Prognosis of Newly Diagnosed Multiple Myeloma Patients
- Author
-
Baoan Chen, Lin Gin, Jinning Shi, Wei Zhang, Wenjing Zhang, and Fei Wang
- Subjects
Creatinine ,medicine.medical_specialty ,Univariate analysis ,Multivariate analysis ,business.industry ,Proportional hazards model ,fungi ,Newly diagnosed ,medicine.disease ,Gastroenterology ,body regions ,chemistry.chemical_compound ,chemistry ,Internal medicine ,Overall survival ,General Earth and Planetary Sciences ,Medicine ,business ,Survival analysis ,Multiple myeloma ,General Environmental Science - Abstract
Objective: To explore the significance of the ratio of neutrophils to lymphocytes (NLR), monocytes to lymphocytes (MLR), and platelets to lymphocytes (PLR) in the prognosis of patients with newly diagnosed multiple myeloma. Methods: A total of 60 patients with MM who were diagnosed in Jiangning Hospital Affiliated to Nanjing Medical University and Zhongda Hospital Affiliated to Southeast University from August 2011 to March 2020 were retrospectively analysed. According to NLR, MLR, PLR, the patients were divided into the low NLR group (NLR < 3.61) or high NLR group (NLR ≥ 3.61), low MLR group (MLR < 0.33) or high MLR group (MLR ≥ 0.33), low PLR group (PLR < 129.78) and high PLR group (PLR ≥ 129.78). Overall survival (OS) was used as the prognostic evaluation criteria, and Kaplan-Meier survival curve, Log-rank test and Cox regression model were used to carry out univariate and multivariate analysis on clinical and laboratory parameters. Results: Among the 60 patients, 33 were male and 27 were female, the median age of the patients was 65 years old, 19 were in the high NLR group, 41 were in the low NLR group, 24 were in the high MLR group, 36 were in the low MLR group, 26 were in the high PLR group, and 34 were in the low PLR group. The univariate analysis showed the prognosis was influenced by factors including NLR, PLR, age, ISS stages, hemoglobin (HGB), albumin (ALT). MLR, type of immunoglobulin, white globulin ratio (A/G), gender, β2-microglobulin(β2-MG), lactate dehydrogenase (LDH) and creatinine were not correlated with the total survival time of patients. The multivariate analysis showed that ISS III stages, PLR ≥ 129.78, HGB < 100g/L were independent risk factors influencing the prognosis of MM patients. Conclusion: ISS III stages, PLR ≥ 129.78, HGB < 100g/L are independent prognostic risk factors in newly diagnosed multiple myeloma patients, which can be used as an economical and effective method for early evaluation of patient prognosis.
- Published
- 2020
22. Study on the Administration Method of Combining Tetrandrine with Adriamycin to Reverse Drug-Resistance of Leukemia
- Author
-
Baoan Chen, Fang Zhou, Jian Cheng, Huihui Song, Yiqian Zhu, and Zheng Shi
- Subjects
Cell growth ,Cell ,Drug resistance ,Pharmacology ,Tetrandrine ,Multiple drug resistance ,chemistry.chemical_compound ,medicine.anatomical_structure ,chemistry ,Cell culture ,Cancer cell ,medicine ,General Earth and Planetary Sciences ,Intracellular ,General Environmental Science - Abstract
Increasing drug efflux pumps (P-gp) on the cell membrane due to the overexpression of MDR1 gene in tumor cells is the main mechanism of multidrug resistance of cancer cells. P-gp belongs to the ATP-binding cassette family and functions as a transmembrane efflux pump that translocates chemotherapy drugs from an intracellular to an extracellular domain; thus, it is impossible to achieve efficient drug accumulation in tumor cells. Tetrandrine (TTD) has been shown in both in vitro and in animal experiments to reverse MDR by reducing the expression of MDR1 mRNA and P-gp. However, the effect of administration of TTD one week before chemotherapy is not ideal in the current clinical trials. In view of the previous in vitro and animal experiments have confirmed the effect of TTD in reversing the drug resistance of leukemia, this study returned to the cell experiment, selected K562 and K562/ADM cell lines as the research object, through different ADM combined with TTD administration sequences, to detect the inhibitory effect of different administration sequences on cell proliferation and whether it affected the intracellular ADM concentration, P- gp ATPase activity, MDR1 mRNA and P-gp expression levels, comparing the effect of TTD combined with ADM different administration sequences on the reversal of MDR in K562/ADM cells. We found that TTD can significantly antagonize P-gp-mediated ADM resistance by competitively binding P-gp and down-regulating P-gp expression and we, therefore, conclude that the co-administration of TTD, as a drug resistance reversal agent with ADM may be a better administration in the clinic.
- Published
- 2020
23. Low Prognostic Nutritional Index Indicates Dismal Prognosis in Patients with Diffuse Large B Cell Lymphoma
- Author
-
Baoan Chen, Chunyan Luan, Jing Zhang, and Xue Wu
- Subjects
Oncology ,medicine.medical_specialty ,Performance status ,business.industry ,CHOP ,medicine.disease ,International Prognostic Index ,B symptoms ,hemic and lymphatic diseases ,Internal medicine ,medicine ,General Earth and Planetary Sciences ,Stage (cooking) ,Risk factor ,medicine.symptom ,business ,Diffuse large B-cell lymphoma ,Body mass index ,General Environmental Science - Abstract
Background: Prognostic nutritional index (PNI) is calculated based on serum albumin concentration and absolute lymphocyte count, and its prognostic value has been established in various human malignancies. However, whether PNI can be applied in predicting the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) remains to be clarified. The aim of the present study is to explore the prognostic value of baseline PNI in DLBCL. Methods: We retrospectively reviewed the medical records of 98 patients with DLBCL treated at the Southeast University-affiliated Zhongda Hospital between January 2013 and November 2019. The optimal cut-off value of PNI was determined using a receiver operating characteristic (ROC) curve and the Youden index. The relationship of high and low PNI with the clinical characteristics of the patients and prognosis were analyzed. Results: Patients with low PNI tended to have a worse event-free survival (EFS) and overall survival (OS) (EFS, P=0.029; OS, P
- Published
- 2020
24. Expression of the SAR2-Cov-2 receptor ACE2 reveals the susceptibility of COVID-19 in non-small cell lung cancer
- Author
-
Hongming Zhang, Runzhe Chen, Jibei Chen, Kelly Quek, and Baoan Chen
- Subjects
0301 basic medicine ,Coronavirus disease 2019 (COVID-19) ,receptor ,ACE2 ,survival ,03 medical and health sciences ,0302 clinical medicine ,Downregulation and upregulation ,expression ,Medicine ,Receptor ,Lung cancer ,Lung ,SARS-CoV-2 ,business.industry ,COVID-19 ,Cancer ,medicine.disease ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,DNA methylation ,Cancer research ,Non small cell ,business ,hormones, hormone substitutes, and hormone antagonists ,Research Paper - Abstract
Recent studies have revealed that cancer patients had a higher risk of having coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), compared to patients without cancer. The expression of angiotensin-converting enzyme 2 (ACE2), the receptor of SARS-CoV-2, was aberrantly expressed in many tumors. In this study, by exploring the TCGA and GTEx public databases, we investigated ACE2 expression and its association with prognosis in non-small cell lung cancer (NSCLC), the most susceptible caner type. We found that lung was one of the major organs with highly expressed ACE2. Furthermore, ACE2 expression was significantly elevated in lung adenocarcioma (LUAD) and lung squamous cell carcinoma (LUSC) compared to normal tissues. DNA methylation might be one possible mechanism leading to ACE2 upregulation. Despite that, the AEC2 expression was not statistically associated with disease-free survival (DFS) and overall survival (OS) for LUAD patients, and higher ACE2 expression was associated with prolonged DFS in LUSC patients. Taken together, we observed ACE2 was highly expressed in LUAD and LUSC despite the controversial role of ACE2 expression in predicting prognosis in these two common lung cancer types.
- Published
- 2020
25. Cytotoxic effects of a sesquiterpene β-elemene on THP-1 leukemia cells is mediated via crosstalk between beclin-1 mediated autophagy and caspase-dependent apoptosis
- Author
-
Joe Antony Jacob, Arivalagan Pugazhendhi, Jingbing Liu, Rajasree Shanmuganathan, Rajesh Mani, Baoan Chen, and Ziyu Jiang
- Subjects
0106 biological sciences ,0303 health sciences ,Autophagy ,Bioengineering ,01 natural sciences ,Applied Microbiology and Biotechnology ,Biochemistry ,Caspase-Dependent Apoptosis ,food.food ,03 medical and health sciences ,chemistry.chemical_compound ,food ,chemistry ,Apoptosis ,010608 biotechnology ,Cancer research ,Cytotoxic T cell ,THP1 cell line ,Elemene ,Curcuma zedoaria ,Cytotoxicity ,030304 developmental biology - Abstract
β- elemene extracted from Curcuma zedoaria rhizome (commonly known as white turmeric) is an effective anticancer agent. There are limited reports on the use of this agent against THP-1 cells employing a mechanistic study. Therefore, as a foremost aim of the present study, the cytotoxic effect of elemene and its mechanism will be elucidated. For this aim, the method adopted was to treat THP-1 cells in a dose- and time- dependent manner with elemene and the cytotoxicity to be evaluated. The mRNA expressions of a set of autophagy and apoptosis related genes will be analyzed by quantitative PCR. The findings indicate that the IC50 values for 24, 48, 72 and 96 h of treated THP-1 cells were 64.71, 42.19, 25.29 and 20.21 μg/mL respectively. The expressions of autophagy related genes such as Beclin-1, LC3II, ATG-5 and XBP-1 were upregulated. The expressions of anti-apoptotic Bcl2 was upregulated, whereas, the expression of pro-apoptotic Bax was downregulated. Interestingly, the expressions of Caspase-3 and Caspase-8 were upregulated. To summarize, autophagy might have occurred in endoplasmic reticulum and there might be a crosstalk with apoptosis which could be the rationale behind the cytotoxic effects of elemene on THP-1 cells. Therefore, β- elemene could be a potential therapeutic agent for leukemia.
- Published
- 2019
26. A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients
- Author
-
Zheng-Ping Yu, Aining Sun, Jia-Hua Ding, Zheng Ge, Depei Wu, and Baoan Chen
- Subjects
Adult ,Male ,medicine.medical_specialty ,Transplantation Conditioning ,Cyclophosphamide ,Primary Immunodeficiency Diseases ,Graft vs Host Disease ,Biology ,Gastroenterology ,Umbilical cord ,Immune Reconstitution ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Granulocyte Colony-Stimulating Factor ,medicine ,Humans ,Transplantation, Homologous ,Cumulative incidence ,Busulfan ,Antilymphocyte Serum ,Umbilical Cord Blood Transplantation ,Graft Survival ,Cytarabine ,Anemia, Aplastic ,Cell Biology ,Hematology ,Middle Aged ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Survival Analysis ,Semustine ,Fludarabine ,Transplantation ,Leukemia, Myeloid, Acute ,Treatment Outcome ,surgical procedures, operative ,medicine.anatomical_structure ,Myelodysplastic Syndromes ,Female ,Cord Blood Stem Cell Transplantation ,Stem cell ,Unrelated Donors ,Immunosuppressive Agents ,Vidarabine ,Developmental Biology ,medicine.drug - Abstract
This study included data from 81 consecutively enrolled patients with hematological diseases who had been treated with unrelated umbilical cord blood transplantation (UCBT) between September 2014 and April 2019. All patients received intense conditioning regimens with combined fludarabine and high-dose cyclophosphamide (FC) before undergoing UCBT. Sixty-seven patients received a single UCBT, and 14 patients received a double UCBT. Fifty patients were pretreated with the fludarabine, busulfan, and cyclophosphamide (FBC) protocol, while 31 patients were treated with FC before transplantation. Graft-versus-host disease (GVHD) was prevented with cyclosporine A and mycophenolate mofetil administration. According to low-resolution, human leukocyte antigen (HLA) donor-recipient matching at six sites, 53 patients had 5-6 matches, while 28 patients had 4 matches. Seventy-eight patients (96.3%) achieved complete engraftment in this study. Thirty-six patients developed acute GVHD (aGVHD). The cumulative incidence of grade I-II aGVHD at day 100 posthematopoietic stem cell transplantation was 29.6%, and the cumulative incidence of grade III-IV aGVHD was 14.8%. At the end of the follow-up, 12 patients died due to treatment-related complications, and 4 died of disease relapse after transplantation. The transplant-related deaths were due to transplant-related infection (8 of 81), GVHD (2 of 81), and organ toxicity (2 of 81). The probability of overall survival (OS) was 80.2%. A higher dose of cyclophosphamide combined with fludarabine conditioning in UCBT was an effective curative method for treatment of hematologic disorders and could enhance the engraftment of umbilical cord blood stem cells, promote post-transplant immune reconstitution, and improve OS.
- Published
- 2019
27. Efficacy of Remdesivir for COVID-19
- Author
-
Hongming, Zhang, Jibei, Chen, Xiyong, Wang, and Baoan, Chen
- Subjects
Alanine ,SARS-CoV-2 ,Humans ,Antiviral Agents ,Adenosine Monophosphate ,COVID-19 Drug Treatment - Abstract
Remdesivir is a broad-spectrum antiviral agent. With the rapid spread of Coronavirus disease 2019 (COVID-19) globally, remdesivir is taking the spotlight for COVID-19 treatment. Despite the promising signs of anti-CoV activity in several preclinical and clinical studies, more data of remdesivir in the treatment of COVID-19 is still needed for evaluating its efficacy.
- Published
- 2021
28. ZNF384 Gene Rearrangement in Acute Lymphocytic Leukemia with Kidney Involvement as the First Manifestation is Associated with Poor Prognosis: A Case Report
- Author
-
Jiaheng Guan, Jinlong Ma, and Baoan Chen
- Subjects
Poor prognosis ,Kidney ,medicine.anatomical_structure ,business.industry ,Acute lymphocytic leukemia ,Cancer research ,Medicine ,Gene rearrangement ,business ,medicine.disease ,ZNF384 - Abstract
Background: Novel fusion genes such as ZNF384 have been identified in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in recent years. Patients harboring ZNF384 rearrangement have a distinctive immunophenotype with weak CD10 and aberrant CD13 and/or CD33 expression, which makes ZNF384-rearranged ALL a unique subtype of BCP-ALL. However, research on the prognostic significance of ZNF384 rearrangement has been limited to date.Case presentation: We described a 17-year-old young woman who was diagnosed with ALL and had kidney involvement as the first manifestation, which was very rare in the existing studies. FISH analysis indicated a rearrangement of ZNF384 according to its probe. The patient had a typical characteristic immunophenotype of ZNF384 rearrangement with CD10 being negative but CD13 and CD33 being positive. She had an unfavorable prognosis since she responded poorly to chemotherapy and developed a relapse shortly after reaching CR.Conclusion: The importance of the ZNF384 gene rearrangement in terms of prognosis remains unclear. We reported a young woman harboring ZNF384 rearrangement in ALL with kidney involvement. She experienced different treatments, but her prognosis remained poor. Since ZNF384 rearrangement may act as a negative prognostic predictor, early detection based on its characteristic immunophenotype is of great necessity.
- Published
- 2021
29. RAC1, a Potential Diagnostic and Prognostic Marker for Diffuse Large B Cell Lymphoma
- Author
-
Xue Wu, Yuan Li, Wandong Zhang, Jing Zhang, Baoan Chen, and Zheng Ge
- Subjects
General Medicine ,RAC 1 ,DLBCL ,diagnosis ,prognosis - Abstract
The gene changes for diagnosis and prognosis of diffuse large B cell lymphoma (DLBCL) still remain unclear. RAC1 was reported to be asso;ciated with the B cell receptor signal pathway, but its relations with DLBCL have not yet been systematically explored. In this study, we have conducted molecular, bioinformatics and clinical analyses by using publicly available data from The Cancer Genome Atlas (TCGA). Wilcoxon signed-rank test and logistic regression were performed to evaluate the association between RAC1 and clinical features in patients. Kaplan–Meier and Cox regression methods were used to examine the impacts of RAC1 expression level on overall survival, and a nomogram was performed to illustrate the correlation between RAC1 and the risk of DLBCL. Our results revealed that the expression level of RAC1 in DLBCL was higher than that in normal tissues or lymphadenitis. High-level expression of RAC1 was significantly associated with clinical stage, as well as being an independent factor affecting overall survival. RAC1 was negatively correlated with Bruton’s tyrosine kinase (BTK). The association between RAC1 gene expression and the risk of DLBCL was presented in a nomogram. In conclusion, RAC1 expression patterns may be used to predict the development and prognosis of DLBCL.
- Published
- 2022
30. Corrections to: Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma
- Author
-
Peng Yuan, Jinhua Song, Fei Wang, Guangyu Zhu, and Baoan Chen
- Subjects
Pharmacology ,Oncology ,Pharmacology (medical) - Published
- 2022
31. ZNF384 rearrangement in acute lymphocytic leukemia with renal involvement as the first manifestation is associated with a poor prognosis: a case report
- Author
-
Jinlong Ma, Jiaheng Guan, and Baoan Chen
- Subjects
Biochemistry (medical) ,Genetics ,Molecular Medicine ,Molecular Biology ,Biochemistry ,Genetics (clinical) - Abstract
Background Novel fusion genes such as ZNF384, have been identified in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in recent years. Patients harboring ZNF384 rearrangements have a distinctive immunophenotype with weak CD10 and aberrant CD13 and/or CD33 expression. Thus, ZNF384-rearranged ALL is a unique subtype of BCP-ALL. However, research on the prognostic significance of ZNF384 rearrangements has been limited to date, especially in adolescents. Case presentation We described a 17-year-old adolescent who was diagnosed with ALL and had renal involvement as the first manifestation, which was very rare in the existing studies. FISH analysis indicated a rearrangement of ZNF384 according to its probe. The patient had a typical characteristic immunophenotype of ZNF384 rearrangement, with CD10 negativity and CD13 and CD33 positivity. She had an unfavorable prognosis because she responded poorly to chemotherapy and developed a relapse shortly after reaching CR. Conclusion The importance of ZNF384 rearrangements in terms of prognosis remains unclear. We reported an adolescent who was diagnosed with ZNF384-rearranged ALL with renal involvement. She underwent different therapies, but her prognosis remained poor. Since ZNF384 rearrangements may act as a prognostic predictor in children or adolescents, early detection based on its characteristic immunophenotype is of great necessity.
- Published
- 2021
32. Tumor‐derived exosomal miR‐19b‐3p facilitates M2 macrophage polarization and exosomal LINC00273 secretion to promote lung adenocarcinoma metastasis via Hippo pathway
- Author
-
Yin Wu, Kai Zhang, Jinyu Bai, Xuerong Wang, Jing Chen, Baoan Chen, and Yingru Zhi
- Subjects
Medicine (General) ,Lung Neoplasms ,Medicine (miscellaneous) ,Adenocarcinoma of Lung ,NEDD4 ,Exosomes ,Exosome ,Metastasis ,R5-920 ,Cell Line, Tumor ,medicine ,Humans ,exosome ,Secretion ,STAT3 ,Research Articles ,Hippo signaling pathway ,biology ,Chemistry ,Macrophages ,Macrophage Activation ,lung adenocarcinoma ,M2 Macrophage ,medicine.disease ,hippo signaling pathway ,Microvesicles ,MicroRNAs ,miR‐19b‐3p ,A549 Cells ,Cancer research ,biology.protein ,Molecular Medicine ,RNA, Long Noncoding ,M2 macrophage polarization ,Research Article - Abstract
Numerous reports have elucidated the important participation of exosomes in the communication between tumor cells and other cancer‐related cells including tumor‐associated macrophages (TAMs) in microenvironment. However, the interchange of exosomes between tumor cells and TAMs in the progression of lung adenocarcinoma (LUAD) remains largely enigmatic. Herein, we discovered that LUAD cells induced the M2 polarization of TAMs and the M2‐polarized macrophages facilitated LUAD cell invasion and migration and tumor metastasis in vivo. In detail, LUAD cells secreted exosomes to transport miR‐19b‐3p into TAMs so that miR‐19b‐3p targeted PTPRD and inhibited the PTPRD‐mediated dephosphorylation of STAT3 in TAMs, leading to STAT3 activation and M2 polarization. Also, the activated STAT3 transcriptionally induced LINC00273 in M2 macrophages and exosomal LINC00273 was transferred into LUAD cells. In LUAD cells, LINC00273 recruited NEDD4 to facilitate LATS2 ubiquitination and degradation, so that the Hippo pathway was inactivated and YAP induced the transcription of RBMX. RBMX bound to miR‐19b‐3p to facilitate the packaging of miR‐19b‐3p into LUAD cell‐derived exosomes. Collectively, our results revealed the mechanism underlying the interactive communication between LUAD cells and TAMs through elucidating the exchange of exosomal miR‐19b‐3p and LINC00273 and proved the prometastatic effect of the interchange between two cells. These discoveries opened a new vision for developing LUAD treatment., LUAD cell‐derived exosomal miR‐19b‐3p induce M2 polarization in THP‐1 cells by targeting PTPRD/STAT3 and STAT3 activated LINC00273 was transmitted by M2 macrophage‐derived exosomes to LUAD cells, activating YAP to induce RBMX‐mediated packaging of miR‐19b‐3p into LUAD cell‐derived exosomes.
- Published
- 2021
33. Clinical application of obinutuzumab for treating chronic lymphocytic leukemia
- Author
-
Baoan Chen and Chunyan Luan
- Subjects
0301 basic medicine ,medicine.drug_class ,Chronic lymphocytic leukemia ,Pharmaceutical Science ,Monoclonal antibody ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,immune system diseases ,Obinutuzumab ,Chemoimmunotherapy ,hemic and lymphatic diseases ,Drug Discovery ,Medicine ,Pharmacology ,CD20 ,biology ,Nucleoside analogue ,business.industry ,medicine.disease ,030104 developmental biology ,chemistry ,030220 oncology & carcinogenesis ,Monoclonal ,Cancer research ,biology.protein ,Rituximab ,business ,medicine.drug - Abstract
Alkylators and nucleoside analogs were the main drugs for treatingchronic lymphoblastic leukemia (CLL), which have been replaced by monoclonal antibodies, such as rituximab in the past 10 years for refractory or relapsed CLL. The first-line immunochemotherapy regimen, rituximab combined with nucleoside analogs, significantly increased CLL patients' first-reaction rate and improved progression-free survival. Despite the long-lasting remissions by the use of chemoimmunotherapy, most CLL patients will relapse eventually. The obinutuzumab (GA101), an updated CD20 antibody, that is thought to achieve a more durable response with unique molecular and functional characteristics. Obinutuzumab is a humanized, monoclonal type II CD20 antibody modified by glycoengineering. The glycoengineered Fc portion enhances the binding affinity to the FcγRIII receptor on immune effector cells, resulting in increased antibody-dependent cellular cytotoxicity and phagocytosis. In addition, the type II antibody binding characteristics of obinutuzumab to CD20 lead to an efficient induction of direct non-apoptotic cell death. This review summarizes the results of clinical studies using obinutuzumab and looks forward to its further application in treating CLL clinically.
- Published
- 2019
34. Sorcin: a novel potential target in therapies of cancers
- Author
-
Xinyi Zhou, Baoan Chen, and Xue Wu
- Subjects
0301 basic medicine ,Protein family ,business.industry ,Cancer ,Cell cycle ,medicine.disease ,Viral infection ,Multiple drug resistance ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Cancer research ,medicine ,business - Abstract
Soluble resistance-related calcium-binding protein (sorcin) is a member of the penta-EF-hand protein family. Sorcin is widely distributed in normal human tissues, such as the brain, heart, lymphocytes, kidneys, breast and skin. Findings suggest that sorcin is associated with the regulation of calcium homeostasis, cell cycle and vesicle trafficking. It has been reported that many types of non-neoplastic diseases such as diabetes, viral infection, infertility, and nervous system diseases were affected by the expression of sorcin. One of the main issues is the role of sorcin in neoplastic diseases. Research proved that sorcin can be found to overexpress in cells of several cancers, particularly in the case of multidrug-resistant cancers. Additionally, the researchers proposed that the expression of sorcin was significantly associated with the foundation of multidrug resistance (MDR). All the findings mentioned above emphasized the importance of studying sorcin. This review mainly includes the following aspects: functions of sorcin, role in non-neoplastic and neoplastic diseases, and research related to drugs. To sum up, sorcin is a potential novel target to be studied to deal with MDR.
- Published
- 2019
35. Combination of drugs and carriers in drug delivery technology and its development
- Author
-
Ying Du and Baoan Chen
- Subjects
0301 basic medicine ,Pharmacology ,Drug ,medicine.medical_specialty ,business.industry ,media_common.quotation_subject ,Pharmaceutical Science ,Cancer treatment ,Clinical trial ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Blood circulation ,Drug Discovery ,Drug delivery ,medicine ,Intensive care medicine ,business ,Disease treatment ,media_common - Abstract
The development of drug-loading technology will bring new and rapid development to the treatment of diseases. At present, drug delivery by nanoparticles, erythrocyte, and platelet have been studied extensively. Compared with traditional anticancer drugs, nano-drugs have shown many obvious advantages, disease treatment based on nanotechnology will bring a revolution in cancer treatment. Due to its inherent biocompatibility, large drug load and long half-life in the blood circulation, erythrocyte-inspired antibiotics, and some anticancer drugs delivery systems have also entered the clinical trial stage. At present, there are relatively few studies on drug delivery by platelets as carriers. It is necessary to overcome the shortcomings of platelets, such as easy activation, deformation, thrombosis, and difficult preservation. There are many ways to combine drugs with these carriers, and each has its own advantages and disadvantages. It is necessary to seek the best combination scheme to increase drug loading and reduce the damage to therapeutic components to the carriers, so as to bring more mature and reliable methods for the clinical application of drug delivery technology. Several drug-loading technologies and their development were described according to various categories. The combination of drugs and carriers is summarized for better understanding of its practical application.
- Published
- 2019
36. Applications of daunorubicin-loaded PLGA-PLL-PEG-Tf nanoparticles in hematologic malignancies: an in vitro and in vivo evaluation
- Author
-
Guohua Xia, Ran Liu, Fei Wang, Wen Bao, and Baoan Chen
- Subjects
0301 basic medicine ,Pharmacology ,medicine.diagnostic_test ,Daunorubicin ,Pharmaceutical Science ,humanities ,In vitro ,Flow cytometry ,03 medical and health sciences ,PLGA ,chemistry.chemical_compound ,030104 developmental biology ,0302 clinical medicine ,chemistry ,In vivo ,Apoptosis ,030220 oncology & carcinogenesis ,Drug Discovery ,Drug delivery ,medicine ,Cancer research ,Distribution (pharmacology) ,health care economics and organizations ,medicine.drug - Abstract
Background With the development of drug delivery, novel tools and technological approaches have captured the attention of researchers in recent years. Several target drug delivery systems (DDSs) including nanoparticles (NPs) have been developed as an important strategy to deliver classical medicine. Objective The objective of this study was to evaluate the application of novel daunorubicin (DNR)-loaded poly(lactic-co-glycolic acid)-poly-l-lysine-polyethylene glycol-transferrin (Tf) nanoparticles (DNR-loaded NPs) in hematologic malignancies in vitro and in vivo. Materials and methods DNR-loaded NPs were prepared by the modified double-emulsion solvent evaporation/diffusion method, and its microscopic form was observed under scanning electron microscope. Intracellular distribution of DNR was directly detected by fluorescence microscopy. After establishment of a tumor xenograft model by injecting K562 cells into the left leg of nude mice, the therapeutic effect of the DNR-loaded NPs on the growth of tumors was measured by calculating the tumor size, and the relative expression of Caspase-3 protein was detected by immunohistochemical staining. Furthermore, intracellular concentration of DNR and the extent of cell apoptosis in primary leukemia cells were quantified by flow cytometry. Results DNR-loaded NPs had a spherical shape of about 180 nm in diameter. DNR-loaded NP group showed a significant enhancement of cellular uptake in K562 cells compared with DNR group. Tumor inhibition rate was higher in DNR-loaded NP group in comparison with DNR group, and the relative expression of Caspase-3 protein was upregulated in DNR-loaded NP group compared with DNR group. Furthermore, DNR-loaded NPs obviously increased intracellular concentration of DNR in primary leukemia cells compared with DNR group, but there was no significant difference in primary cell apoptosis between the two groups. These findings suggest that the novel NP DDS can enhance the performance of conventional antitumor drugs and may be suitable for further application in the treatment of hematologic malignancies.
- Published
- 2019
37. Quizartinib (AC220): a promising option for acute myeloid leukemia
- Author
-
Baoan Chen, Zheng Ge, and Fang Zhou
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Breakthrough therapy ,medicine.medical_treatment ,Pharmaceutical Science ,Targeted therapy ,03 medical and health sciences ,chemistry.chemical_compound ,fluids and secretions ,0302 clinical medicine ,hemic and lymphatic diseases ,Internal medicine ,Drug Discovery ,medicine ,PI3K/AKT/mTOR pathway ,Quizartinib ,Pharmacology ,Chemotherapy ,business.industry ,Myeloid leukemia ,hemic and immune systems ,Clinical trial ,Transplantation ,030104 developmental biology ,chemistry ,030220 oncology & carcinogenesis ,embryonic structures ,business - Abstract
Quizartinib is an effective therapy for patients with FLT3-ITD acute myeloid leukemia (AML) by continuing to inhibit the activity of FLT3 gene, leading to apoptosis of tumor cells. Multiple clinical trials have proved that it is effective in relapsed or refractory AML with an FLT3-ITD mutation. In this review, we focus on the characteristics of FLT3/ITD mutations, the mechanism and pharmacokinetics of quizartinib, and the mechanisms of resistance to quizartinib. We also summarize clinical experiences and adverse effects with quizartinib and recommend crucial approaches of quizartinib in the therapy of patients with newly diagnosed AML and patients with relapsed/refractory AML, particularly those with FLT3-ITD mutation. Quizartinib presents its advantages as a very promising agent in the treatment of AML, especially in patients with FLT3-ITD mutations. FLT3/ITD mutation can lead to constitutive autophosphorylation of FLT3 and activation of its downstream effectors including RAS/RAF/MEK, MAPK/ERK, PI3K/AKT/mTOR and JAK/STAT5 signal pathways, while Quizartinib can inhibit these downstream pathways through specific FLT3 inhibition. Quizartinib has received US Food and Drug Administration breakthrough therapy designation in patients with relapsed/refractory FLT3-ITD AML based on clinical trials. A larger sample of clinical trials are needed to verify its safety and efficacy, and the efficacy of quizartinib combined with chemotherapy or allogeneic hematopoietic cell transplantation should also be estimated in clinical trials. Meanwhile, for the side effects of quizartinib, further studies are needed to find a way to reduce its toxicity.
- Published
- 2019
38. Toxic effects of magnetic nanoparticles on normal cells and organs
- Author
-
Ziyu Jiang, Arivalagan Pugazhendhi, Jingbing Liu, Suresh Rajendran, Kuizhong Shan, Joe Antony Jacob, Baoan Chen, and Jie Song
- Subjects
0301 basic medicine ,Chemistry ,Nanoparticle ,Nanotechnology ,General Medicine ,030226 pharmacology & pharmacy ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Drug Delivery Systems ,030104 developmental biology ,0302 clinical medicine ,Pharmaceutical Preparations ,Drug delivery ,Animals ,Humans ,Nanoparticles ,Magnetic nanoparticles ,General Pharmacology, Toxicology and Pharmaceutics ,Magnetite Nanoparticles - Abstract
Magnetic nanoparticles (MNPs) are promising candidates for drug delivery and treatment of various disorders. Toxicity evaluation is a critical point in the development of nanoformulations and therefore, draws considerable attention. Formulations involving individual or combinatorial nanoparticle suspensions might be used for targeted delivery and treatment. This might be a evaluated further for safety related issues considering future medications based on MNPs. Nanoparticle distribution in the body is dependent on its surface characteristics. Size, dose and routes of nanoparticle entry have to be taken into consideration for future assays.
- Published
- 2019
39. Mechanisms of drug resistance in acute myeloid leukemia
- Author
-
Jing Zhang, Yan Gu, and Baoan Chen
- Subjects
0301 basic medicine ,Daunorubicin ,business.industry ,Myeloid leukemia ,Drug resistance ,medicine.disease ,03 medical and health sciences ,Haematopoiesis ,Regimen ,Leukemia ,030104 developmental biology ,0302 clinical medicine ,medicine.anatomical_structure ,Oncology ,hemic and lymphatic diseases ,030220 oncology & carcinogenesis ,Cancer research ,medicine ,Idarubicin ,Pharmacology (medical) ,Bone marrow ,business ,neoplasms ,medicine.drug - Abstract
Acute myeloid leukemia (AML) is a kind of malignant hematopoietic system disease characterized by abnormal proliferation, poor cell differentiation, and infiltration of bone marrow, peripheral blood, or other tissues. To date, the first-line treatment of AML is still based on daunorubicin and cytosine arabinoside or idarubicin and cytosine arabinoside regimen. However, the complete remission rate of AML is still not optimistic, especially in elderly patients, and the recurrence rate after complete remission is still high. The resistance of leukemia cells to chemotherapy drugs becomes the main obstacle in the treatment of AML. At present, the research on the mechanisms of drug resistance in AML is very active. This article will elaborate on the main mechanisms of drug resistance currently being studied, including drug resistance-related proteins and enzymes, gene alterations, micro RNAs, and signal pathways.
- Published
- 2019
40. Inhibition of bleomycin-induced pulmonary fibrosis in mice by the novel peptide EZY-1 purified from Eucheuma
- Author
-
Jingyao Ma, Shang Wu, Biyun Lin, Haitao Zhang, Zuguo Zhao, Jun Wu, Hui Huang, Huajun Yu, Zhan He, Yajun Wang, Baoan Chen, and Zhao Zhang
- Subjects
Male ,0301 basic medicine ,MAPK/ERK pathway ,Eucheuma ,Smad Proteins ,SMAD ,Pharmacology ,Bleomycin ,Mice ,Phosphatidylinositol 3-Kinases ,03 medical and health sciences ,Idiopathic pulmonary fibrosis ,chemistry.chemical_compound ,Transforming Growth Factor beta ,Pulmonary fibrosis ,medicine ,Animals ,Humans ,030109 nutrition & dietetics ,biology ,General Medicine ,Pirfenidone ,medicine.disease ,biology.organism_classification ,Idiopathic Pulmonary Fibrosis ,Mice, Inbred C57BL ,Disease Models, Animal ,030104 developmental biology ,chemistry ,Rhodophyta ,biology.protein ,Vitronectin ,Peptides ,Signal Transduction ,Food Science ,medicine.drug - Abstract
For the first time, a new 16-amino-acid peptide was isolated from Eucheuma, an edible seaweed, and named EZY-1. EZY-1 was used to interfere with bleomycin-induced mice pulmonary fibrosis. The target proteins of EZY-1 were screened by an in vitro pull-down method combined with LC-MS/MS. The results showed that EZY-1 can inhibit the idiopathic pulmonary fibrosis (IPF) induced by bleomycin. The potency and safety of EZY-1 are superior to those of the drug used for clinical treatment, pirfenidone. The results showed that EZY-1 suppresses the TGF-β/Smad, PI3K-Akt-mTOR, Rac1-PAK2-cAb1 and MAPK signal transduction pathways. Proteins such as ERK, Akt, PDGF receptor β, vitronectin, raptor and SHP2 exhibited binding to EZY-1 in an in vitro pull-down assay combined with LC-MS/MS analysis. EZY-1 was confirmed to be an effective component of Eucheuma in the inhibition of IPF. The signalling pathways and target proteins of EZY-1 were preliminarily predicted. This study lays the foundation for the development of new drugs from Eucheuma for the treatment of IPF.
- Published
- 2019
41. Sulfonylurea receptor 1-expressing cancer cells induce cancer-associated fibroblasts to promote non-small cell lung cancer progression
- Author
-
Hongling, Chen, Li, Zhao, Yuting, Meng, Xixi, Qian, Ya, Fan, Quanli, Zhang, Chao, Wang, Fan, Lin, Baoan, Chen, Lin, Xu, Wenbin, Huang, Jing, Chen, and Xuerong, Wang
- Subjects
MicroRNAs ,Cancer Research ,Lung Neoplasms ,Cancer-Associated Fibroblasts ,Oncology ,Carcinoma, Non-Small-Cell Lung ,Cell Line, Tumor ,Glyburide ,Tumor Microenvironment ,Humans ,Exosomes ,Sulfonylurea Receptors ,Cell Proliferation - Abstract
Cancer-associated fibroblasts (CAFs) play a pivotal role in cancer progression; however, how CAFs are induced remains elusive. Sulfonylurea receptor 1 (SUR1) is a tumor-enhancer in non-small cell lung carcinoma (NSCLC). Here, we probed the influence of SUR1-expressing cancer cells on CAFs. Results showed that high SUR1 expression positively correlated with α-SMA positive staining of CAFs in tumor tissues and poor prognosis of NSCLC patients. SUR1 contributed to normal fibroblast (NF) transformation into CAFs and facilitated the growth and metastasis of NSCLC in vivo. Conditioned medium (CM) and exosomes from SUR1-expressing cancer cells induced CAFs and promoted fibroblast migration. In cancer cells, SUR1 promoted p70S6K-induced KH-type splicing regulatory protein (KHSRP) phosphorylation at S395 to inhibit the binding of KHSRP with let-7a precursor (pre-let-7a) and decreasing mature let-7a-5p expression in cancer cells and exosomes. Let-7a-5p delivered by exosomes blocked NF transformation into CAFs by targeting TGFBR1 to inactivate the TGF-β signaling pathway. Glibenclamide, which targets SUR1, restrained CAFs and suppressed tumor growth in patient-derived xenograft models. Furthermore, we found that let-7a-5p was decreased in the tissues and plasma exosomes of NSCLC patients. In summary, SUR1-expressing cancer cells induce NF transformation into CAFs in the tumor microenvironment and promote NSCLC progression by transferring less exosomal let-7a-5p. Glibenclamide is a promising anti-cancer drug, and plasma exosomal let-7a-5p level is a potential diagnostic biomarker for NSCLC patients. These findings provide new therapeutic strategies by targeting SUR1 in NSCLC.
- Published
- 2022
42. Human cytomegalovirus infection: A considerable issue following allogeneic hematopoietic stem cell transplantation (Review)
- Author
-
Nan Jin, Xinyi Zhou, and Baoan Chen
- Subjects
0301 basic medicine ,Human cytomegalovirus ,Cancer Research ,medicine.medical_treatment ,Congenital cytomegalovirus infection ,Review ,Hematopoietic stem cell transplantation ,cellular immunotherapy ,Virus ,03 medical and health sciences ,0302 clinical medicine ,allo-HSCT ,medicine ,hematological malignancy ,business.industry ,CMV ,virus diseases ,Cancer ,Cell cycle ,medicine.disease ,Molecular medicine ,surgical procedures, operative ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Immunology ,Molecular mechanism ,prophylaxis ,business ,preemptive treatment - Abstract
Cytomegalovirus (CMV) is an opportunistic virus, whereby recipients are most susceptible following allogeneic hematopoietic stem cell transplantation (allo-HSCT). With the development of novel immunosuppressive agents and antiviral drugs, accompanied with the widespread application of prophylaxis and preemptive treatment, significant developments have been made in transplant recipients with human (H)CMV infection. However, HCMV remains an important cause of short- and long-term morbidity and mortality in transplant recipients. The present review summarizes the molecular mechanism and risk factors of HCMV reactivation following allo-HSCT, the diagnosis of CMV infection following allo-HSCT, prophylaxis and treatment of HCMV infection, and future perspectives. All relevant literature were retrieved from PubMed and have been reviewed.
- Published
- 2021
43. Identification of Molecular and Immune Prognostic Classifiers of Acute Myeloid Leukemia
- Author
-
Baoan Chen and Fang Zhou
- Subjects
Immune system ,Text mining ,business.industry ,Myeloid leukemia ,Medicine ,Identification (biology) ,Computational biology ,business - Abstract
Background Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous hematological malignancy and relapse is the main reason for the poor therapeutic effect and low survival rate. Bioinformatic technology could screen out relative genes that promote the recurrence of AML, providing a theoretical basis for further improving the precision stratification treatment of AML. Methods In this study, gene expression profiles of Dataset Acute Myeloid Leukemia (OHSU, Nature 2018) and GSE134589 were downloaded from cbioportal and GEO, respectively. R software and limma packages were used to identify the DEGs and then run GO enrichment, KEGG pathway, and PPI network. CIBERSORTx was used to enumerate tumor-infiltrating immune cells. Prognosis-related genes were selected by Univariate and multivariate Cox proportional hazards regression analyses and the expression of them were verified by GEPIA. Kaplan–Meier curve analysis could compare the survival time. ROC curve analysis was performed to predict the value of the selected genes. Results Functional analysis showed that the up-regulated DEGs were strikingly enriched in Cytokine-cytokine receptor interaction and positive regulation of cytokine production, and the down-regulated DEGs in the regulation of cell-cell adhesion, TNF signaling pathway. CIBERSORTx analysis revealed that the immune response of AML acted as an intricate network and proceeded in a tightly regulated way. Cox analysis showed that ALDH1L2, KLK1, and LRRN2 were correlated with AML prognosis. Conclusions ALDH1L2, KLK1, and LRRN2 are prognosis-related genes in AML, which may together with some immune pathways, induce poor prognosis, and can be used as potential biomarkers in AML treatment.
- Published
- 2021
44. The clinical efficiency of TACE combined with simultaneous computed tomography-guided radiofrequency ablation for advanced hepatocellular carcinoma
- Author
-
Fei Wang, Guangyu Zhu, Baoan Chen, and Peng Yuan
- Subjects
0301 basic medicine ,Adult ,Male ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Radiofrequency ablation ,Urology ,Computed tomography ,Radiography, Interventional ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,law ,medicine ,Humans ,Pharmacology (medical) ,Chemoembolization, Therapeutic ,Transcatheter arterial chemoembolization ,Propensity Score ,Survival rate ,Objective response ,Aged ,Retrospective Studies ,Pharmacology ,Radiofrequency Ablation ,medicine.diagnostic_test ,business.industry ,Liver Neoplasms ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Survival Rate ,surgical procedures, operative ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Propensity score matching ,Female ,Neoplasm Recurrence, Local ,business - Abstract
Background To investigate the clinical efficiency of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) for advanced hepatocellular carcinoma (HCC). Methods This retrospective study enrolled 177 HCC patients, and they were divided into TACE monotherapy group (n = 129) and TACE + RFA group (n = 48) between January 2015 and October 2017. The objective response rate (ORR), disease control rate (DCR), and the survival outcomes were compared between the TACE monotherapy and the treatment of TACE + RFA after propensity score matching (PSM). Results After PSM matching, the confounding factors had no significant differences between the 48 pairs of patients. The DCR was calculated as 33 (69 %) and 42 (88 %) for the TACE monotherapy group and TACE + RFA group, respectively (P
- Published
- 2020
45. Bio-inspired manufacturing strategies for Platelet Analogues
- Author
-
Meng Wang, Shu Wang, Yan Shen, Jian Luan, and Baoan Chen
- Published
- 2020
46. Comprehensive Expression and Prognosis Analyses of ITGB1 in AML
- Author
-
Xinyi Zhou, Nan Jin, and Baoan Chen
- Abstract
BackgroundAcute myeloid leukemia (AML) is a dangerous type of leukemia. The emergence of multidrug resistance (MDR) and recurrence limits the prognosis and survival of patients. In recent studies, we have known that the bone marrow microenvironment was closely related to the poor prognosis of AML. However, the underlying mechanisms are still far from fully understood. By utilizing the bioinformatics analysis, we screened out integrin β1 (ITGB1) as the hub gene, which is associated with the bone marrow microenvironment mediated changes of AML cells, with expression profile GSE73157 downloaded from National Center for Biotechnology Information-Gene Expression Omnibus (NCBI-GEO) database.MethodsR studio software was used to screen out candidate hub genes and further visualize the differential expression. R package “limma” was to find out differentially expressed genes (DEGs). Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway were conducted by R package “cluster Profiler”. Furthermore, protein-protein interaction (PPI) network was also performed by online tool STRING and software Cytoscape. Last but not least, online tool PrognoScan and GEPIA was utilized for the evaluation of clinical significance of the selected hub gene. P and Cox p value
- Published
- 2020
47. Prognostic nutritional index and the prognosis of diffuse large b-cell lymphoma: a meta-analysis
- Author
-
Chunyan Luan, Fei Wang, Baoan Chen, and Ning Wei
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Subgroup analysis ,Cochrane Library ,lcsh:RC254-282 ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Genetics ,medicine ,In patient ,lcsh:QH573-671 ,030304 developmental biology ,0303 health sciences ,lcsh:Cytology ,business.industry ,Hazard ratio ,Prognostic nutritional index ,Diffuse large B-cell lymphoma ,Prognosis ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Confidence interval ,Lymphoma ,Meta-analysis ,030220 oncology & carcinogenesis ,business ,Research Article - Abstract
Background Some studies have investigated the prognostic value exhibited by the Prognostic Nutritional Index (PNI) in patients suffering diffuse large B-cell lymphoma (DLBCL), but varying results were obtained. In order to determine the specific prognostic value more accurately, a meta-analysis was conducted in this study. Methods Literatures were searched from the China National Knowledge Infrastructure (CNKI), Wanfang, PubMed, Embase, the Cochrane Library, and Web of Science. Pooled hazard ratio (HR) and the 95% confidence interval (CI) were calculated to assess the association between PNI and the overall survival (OS) and the progression-free survival (PFS) of patients with DLBCL. Results Based on seven studies with a total number of 1311 patients, our meta-analysis revealed that low PNI may meant poor OS (HR = 2.14, 95% CI 1.66–2.75, p Conclusion For patients with DLBCL, low PNI may be interpreted as adverse prognosis. More data from European patients are required in this study to avoid analysis bias.
- Published
- 2020
48. HLA-DPA1 gene is a potential predictor with prognostic values in multiple myeloma
- Author
-
Baoan Chen, Fei Wang, and Jie Yang
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Alpha (ethology) ,Down-Regulation ,Biology ,HLA-DP alpha-Chains ,Major histocompatibility complex ,lcsh:RC254-282 ,03 medical and health sciences ,0302 clinical medicine ,Bioinformatics analysis ,Internal medicine ,Gene expression ,Genetics ,medicine ,Humans ,KEGG ,Hypoxia ,Gene ,Survival analysis ,Multiple myeloma ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Prognosis ,Survival Analysis ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,biology.protein ,Bone marrow ,Multiple Myeloma ,Research Article - Abstract
Background Multiple myeloma (MM) is an incurable hematological tumor, which is closely related to hypoxic bone marrow microenvironment. However, the underlying mechanisms are still far from fully understood. We took integrated bioinformatics analysis with expression profile GSE110113 downloaded from National Center for Biotechnology Information-Gene Expression Omnibus (NCBI-GEO) database, and screened out major histocompatibility complex, class II, DP alpha 1 (HLA-DPA1) as a hub gene related to hypoxia in MM. Methods Differentially expressed genes (DEGs) were filtrated with R package “limma”. Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway were performed using “clusterProfiler” package in R. Then, protein-protein interaction (PPI) network was established. Hub genes were screened out according to Maximal Clique Centrality (MCC). PrognoScan evaluated all the significant hub genes for survival analysis. ScanGEO was used for visualization of gene expression in different clinical studies. P and Cox p value Results HLA-DPA1 was finally picked out as a hub gene in MM related to hypoxia. MM patients with down-regulated expression of HLA-DPA1 has statistically significantly shorter disease specific survival (DSS) (COX p = 0.005411). Based on the clinical data of GSE47552 dataset, HLA-DPA1 expression showed significantly lower in MM patients than that in healthy donors (HDs) (p = 0.017). Conclusion We identified HLA-DPA1 as a hub gene in MM related to hypoxia. HLA-DPA1 down-regulated expression was associated with MM patients’ poor outcome. Further functional and mechanistic studies are need to investigate HLA-DPA1 as potential therapeutic target.
- Published
- 2020
49. A SERS-colorimetric dual-mode aptasensor for the detection of cancer biomarker MUC1
- Author
-
Yiping Cui, Shenfei Zong, Kai Zhu, Yizhi Zhang, Yujie Wang, Kuo Yang, Na Li, Zhuyuan Wang, Baoan Chen, and Zhile Wang
- Subjects
Materials science ,Aptamer ,Nanotechnology ,02 engineering and technology ,Spectrum Analysis, Raman ,01 natural sciences ,Biochemistry ,Analytical Chemistry ,Neoplasms ,Biomarkers, Tumor ,Humans ,skin and connective tissue diseases ,Colorimetry ,neoplasms ,Detection limit ,010401 analytical chemistry ,Mucin-1 ,Dual mode ,Aptamers, Nucleotide ,021001 nanoscience & nanotechnology ,Prognosis ,digestive system diseases ,0104 chemical sciences ,Biomarker ,Magnetic nanoparticles ,Naked eye ,0210 nano-technology - Abstract
Human mucin-1 (MUC1) has attracted considerable attention owing to its overexpression in diverse malignancies. Here, for the rapid and efficient detection of MUC1, we present a SERS-colorimetric dual-mode aptasensor, by integrating SERS probes with magnetic separation, which has several distinctive advantages. Using such a dual-mode aptasensor, the colorimetric functionality is distinguishable by the naked eye, providing a fast and straightforward screening ability for the detection of MUC1. Moreover, SERS-based detection greatly improves the detection sensitivity, reaching a limit of detection of 0.1 U/mL. In addition, the combination of SERS and colorimetric method holds the advantages of these two techniques and thereby increases the reliability and efficiency of MUC1 detection. On the one hand, the magnetic nanobeads functionalized with MUC1-specific aptamer were utilized as an efficient capturing substrate for separating MUC1 from biological complex medium. On the other hand, the gold-silver core-shell nanoparticles modified with Raman reporters and the complementary sequences of MUC1 were used as the signal indicator, which could simultaneously report the SERS signal and colorimetric change. This strategy can achieve a good detection range and realize MUC1 analysis in real patients' samples. Thus, we anticipate that this kind of aptasensor would provide promising potential applications in the diagnosis and prognosis of cancers. Graphical abstract.
- Published
- 2020
50. Additional file 1 of HLA-DPA1 gene is a potential predictor with prognostic values in multiple myeloma
- Author
-
Yang, Jie, Wang, Fei, and Baoan Chen
- Subjects
Data_FILES - Abstract
Additional file 1.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.